Trifolium repens

MDxHealth Shareholder Transparency Declaration

Retrieved on: 
Tuesday, February 21, 2023
Arnhold and S. Bleichroeder, Financial Services and Markets Authority (Belgium), Article, Transparency, Disclosure, Furthering Asbestos Claims Transparency Act of 2015, Brussels Stock Exchange, Trifolium repens, Person, Financial services, Partnership, Exercise, FSMA, Security (finance)

IRVINE, CA, and HERSTAL, BELGIUM – 21 February 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notification.

Key Points: 
  • IRVINE, CA, and HERSTAL, BELGIUM – 21 February 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act"), that it received the following notification.
  • The Company was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights crossed below the threshold of 15% of the outstanding shares and voting rights of mdxhealth on 03 February 2023.
  • Notably, it follows from the notification that an aggregate of 38,783,335 shares of mdxhealth, representing 14.75% of the 262,880,936 outstanding shares and voting rights of mdxhealth, is held through the following entities: 21 April Fund LP (8,024,518 shares), 21 April Fund LTD (20,342,162 shares), Hill Family Alternative Investments LLC (10,000,000 shares), and White Clover SA (416,670 shares) (the "Funds").
  • Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

MDxHealth Shareholder Transparency Declarations

Retrieved on: 
Monday, November 22, 2021
Article, Disclosure, Private limited company, Trifolium repens, Company, Cayman Islands, FSMA, Exercise, Diagnosis, Partnership, Cancer, Euronext, Prognosis, Physician, Financial services, Methylation, Nasdaq, LLC, Association, Transparency, Social media, Digital Accountability and Transparency Act of 2013, CA, Arnhold and S. Bleichroeder, Person, Financial Services and Markets Authority (Belgium), Security (finance)

MDxHealth was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed below the threshold of 3% of the outstanding shares and voting rights of MDxHealth on 16 November 2021.

Key Points: 
  • MDxHealth was notified that the number of shares with respect to which Soleus Capital Management, L.P. can exercise voting rights actively crossed below the threshold of 3% of the outstanding shares and voting rights of MDxHealth on 16 November 2021.
  • Notably, it follows from the notification that the previously reported shares of MDxHealth were held through Soleus Capital Master Fund, L.P., a limited partnership formed in the Cayman Islands.
  • MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 15% of the outstanding shares and voting rights of MDxHealth on 19 November 2021.
  • The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA.

MDxHealth Announces Completion of Initial Public Offering of ADSs in the United States

Retrieved on: 
Monday, November 15, 2021
Cayman Islands, Private limited company, Cancer, Digital Accountability and Transparency Act of 2013, Person, Transparency, Prognosis, Methylation, CA, Exercise, Social media, Trifolium repens, LLC, Association, Article, Partnership, Company, Disclosure, FSMA, Financial services, Diagnosis, Physician, Arnhold and S. Bleichroeder, Nasdaq, Euronext, Financial Services and Markets Authority (Belgium), Security (finance)

MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 10% of the outstanding shares and voting rights of MDxHealth on 4 November 2021.

Key Points: 
  • MDxHealth was notified that the number of shares with respect to which Bleichroeder LP can exercise voting rights actively crossed above the threshold of 10% of the outstanding shares and voting rights of MDxHealth on 4 November 2021.
  • MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
  • For more information, visit mdxhealth .com and follow us on social media at: twitter.com/mdxhealth , facebook.com/mdxhealth and linkedin.com/company/mdxhealth .
  • The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA.